FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Pertti Lipponen

Research Profile

Phenomena

Mitotic Index

Disorders

Concepts & Ideas

Anatomy

Cell Nucleus

Chemicals & Drugs

Procedures

Co-author Network

Publications

TOP 3
Matti Eskelinen; Pertti Lipponen
Usefulness index in nonspecific abdominal pain--an aid in the diagnosis?
Matti Eskelinen; Pertti Lipponen
Usefulness of history-taking in non-specific abdominal pain: a prospective study of 1333 patients with acute abdominal pain in Finland.
Sirpa Aaltomaa; Vesa Kärjä; Pertti Lipponen; Taina Isotalo; JP Kankkunen; Martti Talja; Risto Mokka
Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Pertti Lipponen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Matti Eskelinen; Pertti Lipponen
Usefulness index in nonspecific abdominal pain--an aid in the diagnosis?
Scandinavian journal of gastroenterology 2012;47(12):1475-9.
2012: Matti Eskelinen; Pertti Lipponen
Usefulness of history-taking in non-specific abdominal pain: a prospective study of 1333 patients with acute abdominal pain in Finland.
In vivo (Athens, Greece) 2012;26(2):335-9.
2006: Sirpa Aaltomaa; Vesa Kärjä; Pertti Lipponen; Taina Isotalo; JP Kankkunen; Martti Talja; Risto Mokka
Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.
Anticancer research 2006;26(6C):4873-8.
2005: Sirpa Aaltomaa; Vesa Kärjä; Pertti Lipponen; Taina Isotalo; JP Kankkunen; Martti Talja; Risto Mokka
Reduced alpha- and beta-catenin expression predicts shortened survival in local prostate cancer.
Anticancer research 2005;25(6C):4707-12.
2005: Vesa Kärjä; Sirpa Aaltomaa; Pertti Lipponen; Taina Isotalo; Martti Talja; Risto Mokka
Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy.
Anticancer research 2005;25(6C):4435-8.
2004: Sirpa Aaltomaa; Pertti Lipponen; Vesa Kärjä; Seppo Lundstedt; Jani Lappi; Veli-Matti Kosma
The expression and prognostic value of alpha-, beta- and gamma-catenins in renal cell carcinoma.
Anticancer research 2004;24(4):2407-13.
2002: Sirpa Aaltomaa; Pertti Lipponen; R Tammi; M Tammi; J Viitanen; JP Kankkunen; Veli-Matti Kosma
Strong Stromal Hyaluronan Expression Is Associated with PSA Recurrence in Local Prostate Cancer.
Urologia internationalis 2002;69(4):266-72.
2001: Sirpa Aaltoma; Pertti Lipponen; Veli-Matti Kosma
Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer.
Anticancer research 2001;21(4B):3101-6.
2001: Pertti Lipponen; Sirpa Aaltomaa; Raija Tammi; Markku Tammi; UM Agren; Veli-Matti Kosma
High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer.
European journal of cancer (Oxford, England : 1990) 2001;37(7):849-56.
2001: Sirpa Aaltomaa; Pertti Lipponen; Martti Ala-Opas; Veli-Matti Kosma
Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer.
European urology 2001;39(2):138-44.
2001: Leena P Setälä; Pertti Lipponen; Raija Tammi; Markku Tammi; Matti Eskelinen; Esko Alhava; Veli-Matti Kosma
Expression of CD44 and its variant isoform v3 has no prognostic value in gastric cancer.
Histopathology 2001;38(1):13-20.
2000: Kirsi Ropponen; Jari K Kellokoski; Pertti Lipponen; Matti Eskelinen; L Alanne; Esko M Alhava; Veli-Matti Kosma
Expression of inducible nitric oxide synthase in colorectal cancer and its association with prognosis.
Scandinavian journal of gastroenterology 2000;35(11):1204-11.
2000: Sirpa Aaltomaa; Pertti Lipponen; J Viitanen; JP Kankkunen; Martti Ala-Opas; Veli-Matti Kosma
Prognostic value of CD44 standard, variant isoforms 3 and 6 and -catenin expression in local prostate cancer treated by radical prostatectomy.
European urology 2000;38(5):555-62.
2000: Tapani Liukkonen; Pertti Lipponen; Mika Raitanen; Eero Kaasinen; Martti Ala-Opas; Pertti Rajala; V M Kosma
Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group.
Urological research 2000;28(5):285-92.
2000: Sirpa Aaltomaa; Pertti Lipponen; J Viitanen; JP Kankkunen; Martti Ala-Opas; V M Kosma
The prognostic value of inducible nitric oxide synthase in local prostate cancer.
BJU international 2000;86(3):234-9.
2000: Pertti Lipponen; Sirpa Aaltomaa; Jari K Kellokoski; Martti Ala-Opas; Veli-Matti Kosma
Expression of activator protein 2 in prostate cancer is related to tumor differentiation and cell proliferation.
European urology 2000;37(5):573-8.
1999: Tapani Liukkonen; Pertti Rajala; Mika Raitanen; Erkki Rintala; Eero Kaasinen; Pertti Lipponen
Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group.
European urology 1999;36(5):393-400.
1999: Kirsi Ropponen; Jari K Kellokoski; Pertti Lipponen; Timo Pietiläinen; Matti Eskelinen; Esko M Alhava; Veli-Matti Kosma
p22/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis.
British journal of cancer 1999;81(1):133-40.
1999: Sirpa Aaltomaa; Pertti Lipponen; Martti Ala-Opas; Matti Eskelinen; Kari Syrjänen; Veli-Matti Kosma
Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival.
British journal of cancer 1999;80(12):2001-7.
1999: Sirpa Aaltomaa; Pertti Lipponen; Martti Ala-Opas; Matti Eskelinen; Veli-Matti Kosma
Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer.
British journal of cancer 1999;80(3-4):477-82.
1999: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Martti Ala-Opas; V M Kosma
Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer.
The Prostate 1999;39(1):8-15.
1999: Pertti Lipponen
Apoptosis in breast cancer: relationship with other pathological parameters.
Endocrine-related cancer 1999;6(1):13-6.
1999: Leena P Setälä; Markku Tammi; Raija Tammi; Matti Eskelinen; Pertti Lipponen; UM Agren; Jyrki Parkkinen; Esko M Alhava; Veli-Matti Kosma
Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate.
British journal of cancer 1999;79(7-8):1133-8.
1999: Sirpa Aaltomaa; Matti Eskelinen; Pertti Lipponen
Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival.
The Prostate 1999;38(3):175-82.
1999: Kirsi Ropponen; Matti Eskelinen; Pertti Lipponen; Esko M Alhava; Veli-Matti Kosma
Reduced expression of alpha catenin is associated with poor prognosis in colorectal carcinoma.
Journal of clinical pathology 1999;52(1):10-6.
1998: M Eskelinen; J Ikonen; Pertti Lipponen
Usefulness of history-taking, physical examination and diagnostic scoring in acute renal colic.
European urology 1998;34(6):467-73.
1998: Pertti Lipponen; Sirpa Aaltoma; Veli-Matti Kosma; Martti Ala-Opas; Matti Eskelinen
Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.
The Journal of pathology 1998;186(2):157-64.
1998: Pertti Lipponen; Sirpa Aaltomaa; Matti Eskelinen; Martti Ala-Opas; Veli-Matti Kosma
Expression of p21(waf1/cip1) protein in transitional cell bladder tumours and its prognostic value.
European urology 1998;34(3):237-43.
1998: JM Karjalainen; Matti Eskelinen; S Nordling; Pertti Lipponen; Esko M Alhava; Veli-Matti Kosma
Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.
British journal of cancer 1998;77(11):1917-25.
1998: Kirsi Ropponen; Matti Eskelinen; Pertti Lipponen; Esko Alhava; Veli-Matti Kosma
Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis.
Scandinavian journal of gastroenterology 1998;33(3):301-9.
1998: Kirsi Ropponen; Markku Tammi; Jyrki Parkkinen; Matti Eskelinen; Raija Tammi; Pertti Lipponen; UM Agren; Esko Alhava; Veli-Matti Kosma
Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer.
Cancer research 1998;58(2):342-7.
1998: Leena P Setälä; Veli-Matti Kosma; Pertti Lipponen; Anita Naukkarinen; S Nordling; SM Hollmén; Matti Eskelinen; K Syrjänen; Esko Alhava
Clinical relevance of p53 index and expression of proliferating cell nuclear antigen and Ki-67 in gastric cancer.
Journal of cancer research and clinical oncology 1998;124(9):497-502.
1998: Kimmo Mäkinen; Tapio Hakala; Pertti Lipponen; Esko Alhava; Matti Eskelinen
Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma.
Anticancer research 1998;18(1B):615-8.
1997: Leena P Setälä; S Nordling; Veli-Matti Kosma; Pertti Lipponen; Matti Eskelinen; SM Hollmén; Kari Juhani Syrjänen; Esko M Alhava
Comparison of DNA ploidy and S-phase fraction with prognostic factors in gastric cancer.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 1997;19(6):524-32.
1997: Kirsi Ropponen; Matti Eskelinen; Pertti Lipponen; Esko Alhava; Veli-Matti Kosma
Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer.
The Journal of pathology 1997;182(3):318-24.
1997: Sirpa Aaltomaa; M Hippeläinen; Pertti Lipponen
Bcl-2 and p53 protein expression in aortic, mammary artery and saphenous vein biopsies in patients subjected to open heart surgery.
In vivo (Athens, Greece) 1997;11(4):337-43.
1997: Pertti Lipponen; S Vesalainen
Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy.
The Prostate 1997;32(1):9-15.
1997: Sirpa Aaltomaa; M Hippeläinen; Pertti Lipponen
Cell proliferation in aortic, mammary artery and saphenous vein biopsies in patients subjected to open heart surgery.
In vivo (Athens, Greece) 1997;11(3):243-7.
1997: E Suonio; Pertti Lipponen; Jukka Mäenpää; Kari Syrjänen; Lauri Kangas; L Tuomisto
Mitotic index in the subrenal capsule assay as an indicator of the chemosensitivity of ovarian cancer.
Cancer chemotherapy and pharmacology 1997;41(1):15-21.
1997: Sirpa Aaltomaa; Pertti Lipponen; S Vesalainen; Martti Ala-Opas; Matti Eskelinen; Kari Syrjänen
Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer.
European urology 1997;32(4):410-5.
1997: Sirpa Aaltomaa; Pertti Lipponen; Martti Ala-Opas; Matti Eskelinen; Kari Syrjänen
Prognostic value of Ki-67 expression in renal cell carcinomas.
European urology 1997;31(3):350-5.
1997: Tapani Liukkonen; Pertti Lipponen; M Helle; K E Jauhiainen
Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer. Finnbladder III Group.
Urological research 1997;25(1):1-7.
1997: Leena P Setälä; Pertti Lipponen; Veli-Matti Kosma; S Marin; Matti Eskelinen; K Syrjänen; Esko Alhava
Nuclear morphometry as a predictor of disease outcome in gastric cancer.
The Journal of pathology 1997;181(1):46-50.
1997: Risto Pirinen; Pertti Lipponen; Sirpa Aaltomaa; Kari Syrjänen
Prognostic value of epidermal growth factor expression in breast cancer.
Journal of cancer research and clinical oncology 1997;123(1):63-8.
1996: Kirsi Ropponen; Matti Eskelinen; Veli-Matti Kosma; Pertti Lipponen; P Paakkinen; Esko Alhava
Comparison of classic and quantitative prognostic factors in colorectal cancer.
Anticancer research 1996;16(6B):3875-82.
1996: Leena P Setälä; Veli-Matti Kosma; S Marin; Pertti Lipponen; Matti Eskelinen; K J Syrjänen; Esko M Alhava
Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration.
British journal of cancer 1996;74(5):766-72.
1996: Pertti Lipponen; S Vesalainen; J Kasurinen; Martti Ala-Opas; Kari Syrjänen
A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour.
Anticancer research 1996;16(4A):2095-100.
1996: Pertti Lipponen; Sirpa Aaltomaa; M Eskelinen
Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumours.
Histopathology 1996;28(2):135-40.
1996: Tapani Liukkonen; Pertti Lipponen; M Helle; H K Haapasalo; S Nordling; P Rajala
Expression of MIB-1, mitotic index and S-phase fraction as indicators of cell proliferation in superficial bladder cancer. Finnbladder Group.
Urological research 1996;24(1):61-6.
1996: T Pietiläinen; Pertti Lipponen; Sirpa Aaltomaa; Matti Eskelinen; Veli-Matti Kosma; Kari Syrjänen
The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer.
Journal of cancer research and clinical oncology 1996;122(11):687-92.
1996: Pertti Lipponen
Expression of cathepsin D in transitional cell bladder tumours.
The Journal of pathology 1996;178(1):59-64.
1995: R Pirinen; Pertti Lipponen; Kari Syrjänen
Expression of epidermal growth factor receptor (EGFR) in breast cancer as related to clinical, prognostic and cytometric factors.
Anticancer research 1995;15(6B):2835-40.
1995: E M Toropainen; Pertti Lipponen; K J Syrjanen
Expression of insulin-like growth factor II in female breast cancer as related to established prognostic factors and long-term prognosis.
Anticancer research 1995;15(6B):2669-74.
1995: P Auvinen; Pertti Lipponen; R Johansson; Kari Syrjänen
Prognostic significance of TGF-beta 1 and TGF-beta 2 expressions in female breast cancer.
Anticancer research 1995;15(6B):2627-31.
1995: T Pietiläinen; Pertti Lipponen; Sirpa Aaltomaa; Matti Eskelinen; Veli-Matti Kosma; Kari Syrjänen
Expression of p53 protein has no independent prognostic value in breast cancer.
The Journal of pathology 1995;177(3):225-32.
1995: Matti Eskelinen; Pertti Lipponen; S Nordling
Prognostic evaluation of DNA flow cytometry and histo-morphological criteria in renal cell carcinoma.
Anticancer research 1995;15(5B):2279-83.
1995: Pertti Lipponen; T Pietiläinen; Veli-Matti Kosma; Sirpa Aaltomaa; Matti Eskelinen; Kari Syrjänen
Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis.
The Journal of pathology 1995;177(1):49-55.
1995: S Vesalainen; Pertti Lipponen; M Talja; J Kasurinen; Kari Syrjänen
Nuclear morphometry is of independent prognostic value only in T1 prostatic adenocarcinomas.
The Prostate 1995;27(2):110-7.
1995: Kimmo Mäkinen; Matti Eskelinen; Pertti Lipponen; Esko Alhava
Expression of C-242 antigen in pancreatic ductal adenocarcinoma.
Anticancer research 1995;15(4):1605-8.
1995: T Pietiläinen; Pertti Lipponen; Sirpa Aaltomaa; Matti Eskelinen; Veli-Matti Kosma; Kari Syrjänen
Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival.
Anticancer research 1995;15(3):959-64.
1995: M Aaltonen; Pertti Lipponen; Veli-Matti Kosma; Sirpa Aaltomaa; Kari Syrjänen
Prognostic value of cathepsin-D expression in female breast cancer.
Anticancer research 1995;15(3):1033-7.
1995: Pertti Lipponen; Matti Eskelinen; Kari Syrjänen
Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma.
British journal of cancer 1995;71(4):863-7.
1995: S Vesalainen; Pertti Lipponen; S Nordling; M Talja; Kari Syrjänen
Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biology.
Anticancer research 1995;15(2):569-73.
1995: S Vesalainen; Pertti Lipponen; M Talja; Kari Syrjänen
Mitotic activity and prognosis in prostatic adenocarcinoma.
The Prostate 1995;26(2):80-6.
1995: Pertti Lipponen
Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer.
The Journal of pathology 1995;175(2):203-10.
1995: S Vesalainen; Pertti Lipponen; M Talja; Kari Syrjänen
Biochemical parameters as prognostic factors in prostatic adenocarcinoma.
Acta oncologica (Stockholm, Sweden) 1995;34(1):53-9.
1995: Pertti Lipponen; Tapani Liukkonen
Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer.
Journal of cancer research and clinical oncology 1995;121(1):44-50.
1995: T Pietiläinen; Pertti Lipponen; Sirpa Aaltomaa; Matti Eskelinen; Veli-Matti Kosma; Kari Syrjänen
Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival.
European journal of cancer (Oxford, England : 1990) 1995;31A(3):329-33.
1995: Pertti Lipponen; Matti Eskelinen
Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer.
Journal of cancer research and clinical oncology 1995;121(5):303-8.
1995: S Vesalainen; Pertti Lipponen
Expression of retinoblastoma gene (Rb) protein in T12M0 prostatic adenocarcinoma.
Journal of cancer research and clinical oncology 1995;121(7):429-33.
1995: E Toropainen; Pertti Lipponen; Kari Syrjänen
Expression of insulin-like growth factor I (IGF-I) in female breast cancer as related to established prognostic factors and long-term prognosis.
European journal of cancer (Oxford, England : 1990) 1995;31A(9):1443-8.
1994: F Chang; Pertti Lipponen; A Tervahauta; Stina Syrjänen; Kari Syrjänen
Transitional cell carcinoma of the bladder: failure to demonstrate human papillomavirus deoxyribonucleic acid by in situ hybridization and polymerase chain reaction.
The Journal of urology 1994;152(5 Pt 1):1429-33.
1994: Kimmo Mäkinen; Matti Eskelinen; Pertti Lipponen; P Pasanen; P Nuutinen; Esko Alhava
Argyrophilic nucleolar organizer regions may help the differential diagnostic distinction between chronic pancreatitis and pancreatic ductal adenocarcinoma.
Scandinavian journal of gastroenterology 1994;29(11):1029-33.
1994: Pertti Lipponen; E Saarelainen; Hongxiu Ji; Sirpa Aaltomaa; Kari Syrjänen
Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer.
The Journal of pathology 1994;174(2):101-9.
1994: S Vesalainen; S Nordling; Pertti Lipponen; M Talja; Kari Syrjänen
Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy.
British journal of cancer 1994;70(2):309-14.
1994: Matti Eskelinen; J Ikonen; Pertti Lipponen
Contributions of history-taking, physical examination, and computer assistance to diagnosis of acute small-bowel obstruction. A prospective study of 1333 patients with acute abdominal pain.
Scandinavian journal of gastroenterology 1994;29(8):715-21.
1994: Pertti Lipponen; Sirpa Aaltomaa
Apoptosis in bladder cancer as related to standard prognostic factors and prognosis.
The Journal of pathology 1994;173(4):333-9.
1994: Pertti Lipponen; Matti Eskelinen
Expression of pS2 protein in transitional cell bladder tumours.
The Journal of pathology 1994;173(4):327-32.
1994: S L Vesalainen; Pertti Lipponen; M T Talja; Esko M Alhava; K J Syrjänen
Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma.
International journal of cancer. Journal international du cancer 1994;58(2):303-8.
1994: Pertti Lipponen; Matti Eskelinen
Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.
British journal of cancer 1994;69(6):1120-5.
1994: Pertti Lipponen; Matti Eskelinen; K Hietala; Kari Syrjänen; R A Gambetta
Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma.
International journal of cancer. Journal international du cancer 1994;57(2):275-80.
1994: S Vesalainen; Pertti Lipponen; M Talja; Esko Alhava; Kari Syrjänen
Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma.
Anticancer research 1994;14(2B):709-14.
1994: Pertti Lipponen; Hongxiu Ji; Sirpa Aaltomaa; Kari Syrjänen
Tumour vascularity and basement membrane structure in breast cancer as related to tumour histology and prognosis.
Journal of cancer research and clinical oncology 1994;120(11):645-50.
1994: S Vesalainen; Pertti Lipponen; M Talja; Kari Syrjänen
Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma.
European journal of cancer (Oxford, England : 1990) 1994;30A(12):1797-803.
1994: Pertti Lipponen; Sirpa Aaltomaa; Veli-Matti Kosma; Kari Syrjänen
Apoptosis in breast cancer as related to histopathological characteristics and prognosis.
European journal of cancer (Oxford, England : 1990) 1994;30A(14):2068-73.
1994: Yrjö Collan; M J Eskelinen; S A Nordling; Pertti Lipponen; E Pesonen; L M Kumpusalo; P Pajarinen; K O Kettunen
Prognostic studies in breast cancer. Multivariate combination of nodal status, proliferation index, tumor size, and DNA ploidy.
Acta oncologica (Stockholm, Sweden) 1994;33(8):873-8.
1993: Pertti Lipponen
Image analysis of Ag-NOR proteins in transitional cell bladder cancer.
The Journal of pathology 1993;171(4):279-83.
1993: Pertti Lipponen; Sirpa Aaltomaa; S Papinaho; Kari Syrjänen
Nucleolar organizer regions in myofibroblasts in breast cancer. Relation to cancer cell morphometry, flow cytometry, sex steroid receptor content, tumour histology and prognosis.
Pathology, research and practice 1993;189(9):1030-5.
1993: Matti Eskelinen; Pertti Lipponen; M Hippeläinen; L Seveus; K Syrajänen
Expression of tumour associated antigens 12H12, 2E11, 7A9, CEA and DF3 in human breast cancer.
Anticancer research 1993;13(6B):2399-406.
1993: Matti Eskelinen; Pertti Lipponen; L Aitto-Oja; O Hall; Kari Syrjänen
The value of histoquantitative measurements in prognostic assessment of renal adenocarcinoma.
International journal of cancer. Journal international du cancer 1993;55(4):547-54.
1993: Pertti Lipponen; Matti Eskelinen; K Jauhiainen; R Terho; S Nordling
Proliferation indices as independent prognostic factors in papillary Ta-T1 transitional cell bladder tumours.
British journal of urology 1993;72(4):451-7.
1993: Pertti Lipponen; Sirpa Aaltomaa; Kari Syrjänen
Morphometric quantitation of nucleolar organizer region proteins in breast carcinoma.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 1993;15(5):311-6.
1993: Pertti Lipponen; Hongxiu Ji; Sirpa Aaltomaa; Stina Syrjänen; Kari Syrjänen
p53 protein expression in breast cancer as related to histopathological characteristics and prognosis.
International journal of cancer. Journal international du cancer 1993;55(1):51-6.
1993: M Hippeläinen; Matti Eskelinen; Pertti Lipponen; F Chang; Kari Syrjänen
Mitotic activity index, volume corrected mitotic index and human papilloma-virus suggestive morphology are not prognostic factors in carcinoma of the oesophagus.
Anticancer research 1993;13(3):677-81.
1993: Sirpa Aaltomaa; Pertti Lipponen; Kari Syrjänen
Nucleolar organizer regions related to morphometry, flow cytometry, sex steroid receptor content, tumour histology and prognosis in female breast cancer.
Pathology, research and practice 1993;189(4):416-21.
1993: Sirpa Aaltomaa; Pertti Lipponen; S Papinaho; Veli-Matti Kosma
Mast cells in breast cancer.
Anticancer research 1993;13(3):785-8.
1993: Pertti Lipponen
Stereologically measured nuclear volume in comparison to two-dimensional nuclear morphometry, mitotic index and flow cytometry in predicting disease outcome in bladder cancer.
Anticancer research 1993;13(2):529-32.
1993: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Veli-Matti Kosma; S Marin; Esko Alhava; K Syrjänen
Comparison of classic and quantitative prognostic factors in hormone receptor-positive and hormone receptor-negative female breast cancer.
American journal of surgery 1993;165(3):307-11.
1993: Sirpa Aaltomaa; Pertti Lipponen; Kari Syrjänen
Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer.
Anticancer research 1993;13(2):533-8.
1993: Pertti Lipponen; Matti Eskelinen
Expression of C-50 antigen as a prognostic variable in transitional cell bladder tumours.
British journal of urology 1993;71(2):192-8.
1993: Pertti Lipponen
Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value.
International journal of cancer. Journal international du cancer 1993;53(3):365-70.
1993: Pertti Lipponen; S Nordling; Matti Eskelinen; K Jauhiainen; R Terho; E Harju
Flow cytometry in comparison with mitotic index in predicting disease outcome in transitional-cell bladder cancer.
International journal of cancer. Journal international du cancer 1993;53(1):42-7.
1993: Pertti Lipponen; M Eskelinen; K Jauhiainen; R Terho; E Harju
Clinical prognostic factors in transitional cell cancer of the bladder.
Urologia internationalis 1993;50(4):192-7.
1993: Kimmo Mäkinen; Matti Eskelinen; Pertti Lipponen; P Nuutinen; S Marin; Esko Alhava
Ag-NORs related to flow cytometry, morphometry and prognosis in patients with pancreatic cancer.
Anticancer research 1993;13(1):157-60.
1993: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Veli-Matti Kosma; S Marin; Esko Alhava; Kari Syrjänen
Predictive value of a morphometric prognostic index in female breast cancer.
Oncology 1993;50(1):57-62.
1993: Pertti Lipponen; Matti Eskelinen; K Jauhiainen; E Harju; R Terho; H Haapasalo
Grading of superficial bladder cancer by quantitative mitotic frequency analysis.
The Journal of urology 1993;149(1):36-41.
1993: Pertti Lipponen; Matti Eskelinen; K Jauhiainen; E Harju; R Terho; H Haapasalo
Prognostic factors in nodular transitional cell bladder tumours.
Scandinavian journal of urology and nephrology 1993;27(2):205-10.
1993: Pertti Lipponen
The changing importance of prognostic factors in bladder cancer during a long-term follow-up.
European journal of cancer (Oxford, England : 1990) 1993;29A(9):1261-5.
1993: Pertti Lipponen; Matti Eskelinen; I Hemmilä
Expression of the tumour-associated antigen CA-242 in transitional cell bladder tumours: a comparison with CA-50.
European journal of cancer (Oxford, England : 1990) 1993;29A(14):1935-40.
1993: Pertti Lipponen
Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer.
European journal of cancer (Oxford, England : 1990) 1993;29A(5):749-53.
1993: Sirpa Aaltomaa; Pertti Lipponen; S Papinaho; Kari Syrjänen
Proliferating-cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer.
Journal of cancer research and clinical oncology 1993;119(5):288-94.
1993: Pertti Lipponen
The prognostic value of basement membrane morphology, tumour histology and morphometry in superficial bladder cancer.
Journal of cancer research and clinical oncology 1993;119(5):295-300.
1992: Matti Eskelinen; Pertti Lipponen; Kari Syrjänen
Nucleolar organiser regions (AgNORs) related to histopathological characteristics and survival in prostatic adenocarcinoma.
Anticancer research 1992;12(5):1635-40.
1992: Pertti Lipponen; S Papinaho; Matti Eskelinen; P J Klemi; Sirpa Aaltomaa; Veli-Matti Kosma; S Marin; Kari Syrjänen
DNA ploidy, S-phase fraction and mitotic indices as prognostic predictors of female breast cancer.
Anticancer research 1992;12(5):1533-8.
1992: Pertti Lipponen
Histological and quantitative prognostic factors in transitional cell bladder cancer treated by cystectomy.
Anticancer research 1992;12(5):1527-32.
1992: J Karjalainen; Matti Eskelinen; Veli-Matti Kosma; Pertti Lipponen; L Tuominen; Esko Alhava
Clinical, histological and quantitative prognostic factors in cutaneous malignant melanoma.
Anticancer research 1992;12(5):1507-11.
1992: Pertti Lipponen; Sirpa Aaltomaa; Matti Eskelinen; Veli-Matti Kosma; S Marin; Kari Syrjänen
The changing importance of prognostic factors in breast cancer during long-term follow-up.
International journal of cancer. Journal international du cancer 1992;51(5):698-702.
1992: Matti Eskelinen; Pertti Lipponen; Sirpa Aaltomaa; Veli-Matti Kosma; Kari Syrjänen; Esko Alhava
Breast cancer in young women: clinical, histological and morphometric prognostic factors.
Anticancer research 1992;12(4):1237-42.
1992: Sirpa Aaltomaa; Pertti Lipponen; Kari Syrjänen
Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining.
Anticancer research 1992;12(4):1281-6.
1992: Pertti Lipponen; Matti Eskelinen
Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value.
British journal of cancer 1992;66(1):171-6.
1992: Matti Eskelinen; Pertti Lipponen; S Papinaho; Sirpa Aaltomaa; Veli-Matti Kosma; P Klemi; Kari Syrjänen
DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer.
International journal of cancer. Journal international du cancer 1992;51(4):555-61.
1992: Pertti Lipponen; Matti Eskelinen; K Jauhiainen; E Harju; R Terho; H Haapasalo
Independent clinical, histological and quantitative prognostic factors in transitional-cell bladder tumours, with special reference to mitotic frequency.
International journal of cancer. Journal international du cancer 1992;51(3):396-403.
1992: Pertti Lipponen; Matti Eskelinen; S Papinaho; P J Klemi; Sirpa Aaltomaa; Veli-Matti Kosma; S Marin; Kari Syrjänen
Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.
Anticancer research 1992;12(3):677-82.
1992: Pertti Lipponen; Matti Eskelinen; K Jauhiainen; R Terho; S Nordling
Independent prognostic factors in T2/T3 transitional cell bladder tumours with special reference to histoquantitative methods.
Surgical oncology 1992;1(2):135-43.
1992: Sirpa Aaltomaa; Pertti Lipponen; S Papinaho; P Klemi; Veli-Matti Kosma; S Marin; Matti Eskelinen; Esko Alhava; Kari Syrjänen
Nuclear morphometry and DNA flow cytometry as prognostic factors in female breast cancer.
The European journal of surgery = Acta chirurgica 1992;158(3):135-41.
1992: Pertti Lipponen; Matti Eskelinen
Cell proliferation of transitional cell bladder cancer determined by PCNA/cyclin immunostaining. A histopathological description.
Anticancer research 1992;12(2):577-83.
1992: Matti Eskelinen; Pertti Lipponen; S Marin; H Haapasalo; Kimmo Mäkinen; J Puittinen; Esko Alhava; S Nordling
DNA ploidy, S-phase fraction, and G2 fraction as prognostic determinants in human pancreatic cancer.
Scandinavian journal of gastroenterology 1992;27(1):39-43.
1992: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Veli-Matti Kosma; S Marin; Esko Alhava; K Syrjänen
Mitotic indexes as prognostic predictors in female breast cancer.
Journal of cancer research and clinical oncology 1992;118(1):75-81.
1992: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Veli-Matti Kosma; S Marin; Esko Alhava; K Syrjänen
Prognostic factors after 5 years follow-up in female breast cancer.
Oncology 1992;49(2):93-8.
1992: Pertti Lipponen; Matti Eskelinen
Argyrophilic nucleolar organiser regions in transitional cell bladder tumours related to established prognostic factors, progression and independent prognostic value.
Oncology 1992;49(2):133-8.
1992: Matti Eskelinen; Pertti Lipponen; Kari Syrjänen
Expression of tumour markers CA50, CEA and TPA in female breast carcinoma as related to histopathological findings and survival.
Anticancer research 1992;12(1):91-5.
1992: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Veli-Matti Kosma; S Mari; Esko Alhava; K Syrjänen
Histological assessment of the prognostic factors in female breast cancer.
Oncology 1992;49(1):1-8.
1992: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Veli-Matti Kosma; S Marin; Esko Alhava; K Syrjänen
Lymphocyte infiltrates as a prognostic variable in female breast cancer.
European journal of cancer (Oxford, England : 1990) 1992;28A(4-5):859-64.
1992: Pertti Lipponen; Matti Eskelinen; K Jauhiainen; E Harju; P Terho; H Haapasalo
Prognostic factors in WHO grade 2 transitional-cell bladder cancer (TCC); a novel two-grade classification system for TCC based on mitotic index.
Journal of cancer research and clinical oncology 1992;118(8):615-20.
1992: Pertti Lipponen
Review of cytometric methods in the assessment of prognosis in transitional cell bladder cancer.
European urology 1992;21(3):177-83.
1992: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Veli-Matti Kosma; S Marin; Esko Alhava; Kari Syrjänen
Tumor size, nuclear morphometry, mitotic indices as prognostic factors in axillary-lymph-node-positive breast cancer.
European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes 1992;24(3):160-8.
1992: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen
Demographic prognostic factors in breast cancer.
Acta oncologica (Stockholm, Sweden) 1992;31(6):635-40.
1992: Pertti Lipponen; Matti Eskelinen; K Jauhiainen; E Harju; R Terho
Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer.
European journal of cancer (Oxford, England : 1990) 1992;29A(1):69-75.
1992: Pertti Lipponen; Matti Eskelinen; K Jauhiainen; E Harju; R Terho; H Haapasalo
Prediction of superficial bladder cancer by nuclear image analysis.
European journal of cancer (Oxford, England : 1990) 1992;29A(1):61-5.
1992: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Veli-Matti Kosma; S Marin; Esko Alhava; K Syrjänen
Prediction of outcome after first recurrence of breast cancer.
The European journal of surgery = Acta chirurgica 1992;158(1):13-8.
1992: Pertti Lipponen
[New prognosticators in urinary bladder carcinoma].
Duodecim; lääketieteellinen aikakauskirja 1992;108(21):1843-8.
1992: Matti Eskelinen; Pertti Lipponen
A review of prognostic factors in human pancreatic adenocarcinoma.
Cancer detection and prevention 1992;16(5-6):287-95.
1991: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Veli-Matti Kosma; S Marin; Esko Alhava; K Syrjänen
Prognostic scores combining clinical, histological and morphometric variables in assessment of the disease outcome in female breast cancer.
International journal of cancer. Journal international du cancer 1991;49(6):886-92.
1991: Pertti Lipponen; Matti Eskelinen; J Kiviranta; E Pesonen
Prognosis of transitional cell bladder cancer: a multivariate prognostic score for improved prediction.
The Journal of urology 1991;146(6):1535-40.
1991: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Veli-Matti Kosma; S Marin; Esko Alhava; K Syrjänen
Hormone receptors as prognostic factors in female breast cancer.
Annals of medicine 1991;23(6):643-8.
1991: Pertti Lipponen; Matti Eskelinen; S Nordling
Nucleolar organiser regions (AgNORs) as predictors in transitional cell bladder cancer.
British journal of cancer 1991;64(6):1139-44.
1991: Pertti Lipponen; Yrjö Collan; Matti Eskelinen
Volume corrected mitotic index (M/V index), mitotic activity index (MAI), and histological grading in breast cancer.
International surgery 1991;76(4):245-9.
1991: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Veli-Matti Kosma; S Marin; Esko Alhava; K Syrjänen
Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma.
Anticancer research 1991;11(5):1701-6.
1991: Matti Eskelinen; Pertti Lipponen; Kari Syrjänen
TAG 12 expression as a prognostic factor in female breast cancer.
Anticancer research 1991;11(5):1683-6.
1991: A Tervahauta; Matti Eskelinen; Stina Syrjänen; Pertti Lipponen; P Pajarinen; Kari Syrjänen
Immunohistochemical demonstration of c-erb B-2 oncoprotein expression in female breast cancer and its prognostic significance.
Anticancer research 1991;11(5):1677-81.
1991: Pertti Lipponen; Matti Eskelinen; Yrjö Collan
Immunohistochemical staining of CA 50 antigen in human bladder cancer. Relation to histologic grade, clinical stage, and prognosis.
Urology 1991;38(2):163-9.
1991: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Veli-Matti Kosma; S Marin; Esko Alhava; K Syrjänen
The significance of nuclear morphometric variables as prognostic predictors in breast cancer.
Anticancer research 1991;11(4):1663-9.
1991: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Esko Alhava; Kari Syrjänen
Nuclear morphometry and mitotic indexes as prognostic factors in breast cancer.
The European journal of surgery = Acta chirurgica 1991;157(5):319-24.
1991: Matti Eskelinen; Pertti Lipponen; S Marin; H Haapasalo; Kimmo Mäkinen; H Ahtola; J Puittinen; P Nuutinen; Esko Alhava
Prognostic factors in human pancreatic cancer, with special reference to quantitative histology.
Scandinavian journal of gastroenterology 1991;26(5):483-90.
1991: Pertti Lipponen; Matti Eskelinen; J Kiviranta; S Nordling
Classic prognostic factors, flow cytometric data, nuclear morphometric variables and mitotic indexes as predictors in transitional cell bladder cancer.
Anticancer research 1991;11(2):911-6.
1991: Pertti Lipponen; Matti Eskelinen
How to count mitoses in bladder cancer grading?
Anticancer research 1991;11(2):825-9.
1991: Pertti Lipponen; Matti Eskelinen
Nucleolar organiser regions (NORs) in bladder cancer; relation to histological grade, clinical stage and prognosis.
Anticancer research 1991;11(1):75-80.
1991: Pertti Lipponen; Matti Eskelinen; S Nordling
Relationship between DNA flow cytometric data, nuclear morphometric variables and volume-corrected mitotic index in transitional cell bladder tumors.
European urology 1991;19(4):327-31.
1991: Matti Eskelinen; Pertti Lipponen; R Majapuro; Kari Syrjänen
Prognostic factors in prostatic adenocarcinoma assessed by means of quantitative histology.
European urology 1991;19(4):274-8.
1991: Pertti Lipponen; Matti Eskelinen; M Sotarauta
Prediction of T1-2 GI-II transitional cell bladder cancer; evaluation by histoquantitative methods.
Scandinavian journal of urology and nephrology 1991;25(2):129-34.
1991: Pertti Lipponen; Matti Eskelinen; S Nordling
Progression and survival in transitional cell bladder cancer: a comparison of established prognostic factors, S-phase fraction and DNA ploidy.
European journal of cancer (Oxford, England : 1990) 1991;27(7):877-81.
1991: Matti Eskelinen; Pertti Lipponen; Yrjö Collan; K J Syrjänen
The role of nucleolar organiser regions as prognostic factors in breast cancer.
European journal of cancer (Oxford, England : 1990) 1991;27(8):989-92.
1991: Pertti Lipponen; Matti Eskelinen; S Nordling
Intratumoral heterogeneity of DNA indexes in transitional cell bladder cancer: relation to tumor histology.
European urology 1991;20(4):311-4.
1991: Sirpa Aaltomaa; Pertti Lipponen; Matti Eskelinen; Veli-Matti Kosma; S Marin; Esko Alhava; K Syrjänen
Prognostic factors in axillary lymph node-negative (pN-) breast carcinomas.
European journal of cancer (Oxford, England : 1990) 1991;27(12):1555-9.
1991: Pertti Lipponen; Matti Eskelinen; Stina Syrjänen; A Tervahauta; Kari Syrjänen
Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder.
European urology 1991;20(3):238-42.
1990: Pertti Lipponen; Matti Eskelinen
Nuclear morphometry in grading transitional cell bladder cancer compared with subjective histological grading.
Anticancer research 1990;10(6):1725-30.
1990: Pertti Lipponen; Yrjö Collan; Matti Eskelinen; E Pesonen; M Sotarauta; S Nordling
Comparison of morphometry and DNA flow cytometry with standard prognostic factors in bladder cancer.
British journal of urology 1990;65(6):589-97.
1990: Pertti Lipponen; Matti Eskelinen; Y Collan; S Marin; E Alhava
Volume-corrected mitotic index in human pancreatic cancer. Relation to histologic grade, clinical stage, and prognosis.
Scandinavian journal of gastroenterology 1990;25(6):548-54.
1990: Matti Eskelinen; Pertti Lipponen; Yrjö Collan
Immunohistochemical staining of human breast cancer with a new tumour marker MCA: relation to axillary lymph node involvement, metastasis, and survival.
Anticancer research 1990;10(3):591-6.
1990: Pertti Lipponen; Veli-Matti Kosma; Yrjö Collan; T Kulju; O Kosunen; Matti Eskelinen
Potential of nuclear morphometry and volume-corrected mitotic index in grading transitional cell carcinoma of the urinary bladder.
European urology 1990;17(4):333-7.
1990: Pertti Lipponen; Yrjö Collan; Matti Eskelinen; E Pesonen; M Sotarauta
Volume corrected mitotic index (M/V index) in human bladder cancer; relation to histological grade (WHO), clinical stage (UICC) and prognosis.
Scandinavian journal of urology and nephrology 1990;24(1):39-45.
1990: Pertti Lipponen; Yrjö Collan; Matti Eskelinen; E Pesonen; M Sotarauta
Morphometry in human transitional cell bladder cancer. Nuclear area and standard deviation of nuclear area--relation to tumor grade (WHO) and prognosis.
European urology 1990;17(2):155-60.
1990: Pertti Lipponen; Matti Eskelinen; Yrjö Collan; E Pesonen; T Ventilä; M Sotarauta; S Nordling
DNA ploidy and S phase fraction in human bladder cancer. Relation to survival and histological grade (WHO).
Urologia internationalis 1990;45(1):4-9.
1990: Pertti Lipponen; Matti Eskelinen
Volume-corrected mitotic index and mitotic activity index in transitional cell bladder cancer.
European urology 1990;18(4):258-62.
1990: Pertti Lipponen; Matti Eskelinen; Yrjö Collan
Prognostication of bladder carcinoma by immunohistochemistry: refined and combined analysis of staining for MCA and CA50.
Urologia internationalis 1990;45(6):361-6.
1990: Pertti Lipponen; Matti Eskelinen; M Sotarauta
Prediction of superficial bladder cancer by histoquantitative methods.
European journal of cancer (Oxford, England : 1990) 1990;26(10):1060-3.
1989: Pertti Lipponen; H Simpanen; E Pesonen; Matti Eskelinen; M Sotarauta; Yrjö Collan
Potential of morphometry in grading transitional cell carcinoma of the urinary bladder.
Pathology, research and practice 1989;185(5):617-20.